Tamoxifen and endometrial cancer: New data for an old problem. Review

European Journal of Gynaecological Oncology

Volumn 18, Issue 5, 1997, Pages 429-433

  Leo, L ^a   Tessarolo, M ^a   Febo, G ^a   Farina, C ^a   Nuzzo, L ^a   Arduino, S ^a   Wierdis, T ^a   Lanza, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast neoplasms; Endometrial neoplasms; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; ENDOMETRIUM CANCER; FEMALE; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN;

EID: 0030866656     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Cole M. P., Jones C. J., Todd D. H.: "A new antioestrogenic agent in late breast cancer". Br. J. Cancer, 1971, 25, 270.
2. Parker M. G. et al.: "Function of estrogen receptor as a transcription factor. a target for antiestrogens". In: "Origins of human cancer: a comprehensive review". Cold Spring Harbor Laboratory Press. New York, 1991, 667
3. Gong Y. et al.: "Differential effects of estrogens and antiestrogens on transforming growth factor gene expression in endometrial adenocarcinoma cells". Cancer Res., 1992, 52, 1704.
4. Sakakibara K., Kan N. C., Satyaswaroop P. G.: "Both 17ß-estradiol and tamoxifen induce c-fos messenger ribonucleic acid expression in human endometrial carcinoma grown in nude mice". Am. J. Obstet. Gynecol., 1992, 166, 206.
5. Katzenellenbogen B. S.: "Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy". J. Natl. Cancer Inst., 1991, 83, 1434.
6. Osborne C. K., Coronado E., Alfred D. C., Wiebe V., and De Gregorio M.: "Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxy tamoxifen". J. Natl. Cancer Inst., 1991, 83, 1477.
7. Anteby E , Yagel S , Zacut D., Palti Z., Hochner-Celnikier D.: "False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen". Lancet, 1992, 340, 433.
8. Cohen I., Rosen D J., Shapira J. et al.: "Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer". Br. J. Obstet. Gynaecol., 1993, 100, 567.
9. Nuovo M. A., Nuovo G., McCaffrey R. M., Levine R. U., Barron B., Winkler B.: "Endometrial polyps in postmenopausal patients receiving tamoxifen". Int. J. Gynecol. Pathol, 1989, 8, 125.
10. Pons J. Y., Abeille J. P., Legros R.: "Effets utérins paradoxau du tamoxifène". Gynaecologia, 1983, 4, 573.
11. Neven P., De Muylder X., Van Belle Y. et al.: "Tamoxifen and the uterus and endometrium". Lancet, 1988, 2, 375.
12. De Muylder X., Neven P., De Somer M. et al "Endomeinal lesions in patients undergoing tamoxifen therapy". Int. J. Gynecol Obstet., 1991, 36, 127.
13. Lahti E., Blanco G., Kauppila A. et al.: "Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen". Obstet. Gynecol., 1993, 81, 660.
14. Cohen I., Rosen D. J. D., Shapira J. et al.: "Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer". Br. J. Obstet. Gynecol., 1993, 81, 660.
15. Cohen I., Rosen D. J. D., Shapira J. et al.: "Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic, postmenopausal breast cancer patients". Gynecol. Oncol., 1994, 52, 185.
16. Neven P., De Muylder X., Van Balle Y. et al: "Hysteroscopic follow-up during tamoxifen treatment". Eur. J. Obstet. Gynecol. Reprod. Biol., 1990, 35, 235.
17. Corley D., Rowe J., Curtis M. T. et al.: "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy". Obstet. Gynecol., 1991, 79, III.
18. Cross S. S., Ismail S. M.: "Endometrial hyperplasia in an oophoreclomized woman receiving tamoxifen therapy: case report". Br. J. Obstet. Gynecol., 1990, 97, 190.
19. Gal D., Kopel S., Bashevkim M. et al.: "Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: a preliminary report". Gynecol. Oncol., 1991, 42, 120.
20. Ugwumadu A. H. N., Bower D., Kin-Hoi Ho P.: "Tamoxifen-induced adenomyosis and adenomyomatous endometrial polyp". Br. J Obstet Gynecol., 1993, 100, 386.
21. Killackey M. A., Hakes T. B., Pierce V. K.: "Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens". Cancer Treat. Rep., 1985, 69, 237.
22. Hardell L.: "Tamoxifen as a risk factor for carcinoma of corpus uteri". Lancet, 1988, 3, 563.
23. Ribeiro G., Swindell R.: "The Christie hospital adjuvant tamoxifen trial: status at 10 years". Br. J. Cancer, 1988, 57, 601.
24. Fornander T., Cedermak B., Mattson A. et al.: "Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers". Lancet, 1989, 21, 117.
25. Malfetano J. H.: "Tamoxifen: associated endometrial carcinoma in postmenopausal breast cancer patients". Gynecol Oncol., 1990, 39, 82.
26. Atlante G., Pozzi M., Vincenzoni C. et al.: "Four case reports presenting new acquisitions on the association of breast and endometrial cancer". Gynecol. Oncol., 1990, 37, 378.
27. Mathew A., Chabon A. B , Kabakow B. et al.: "Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy". N.Y. State J. Med., 1990, 90, 207.
28. Spinelli G., Bordazzi N., Citernesi A. et al.: "Endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Chemother., 1991, 3, 276.
29. Rasmussen K. L., Neilsen K. M.: "Development of endometrial cancer during tamoxifen therapy". Ugesker Kaeger, 1991, 53, 2638.
30. Anderson M., Storm H. H., Mouridsen H. T.: "Incidence of new primary cancer after adjuvant tamoxifen therapy and radiotherapy for early breast cancer". J. Natl. Cancer Inst., 1991, 83, 1013.
31. Segna R A , Dottino P. R., Deligdisch L. et al.: "Tamoxifen and endometrial cancer". Mt. Sinai J. Med., 1992, 59, 416.
32. Seoud M. A. F., Johnson J., Weed J. C.: "Gynecologic tumors in tamoxifen-treated women with breast cancer". Obstet. Gynecol., 1993, 82, 165.
33. Magriples U., Naftolin F., Schwartz P. E. et al.: "High grade endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Clin. Oncol., 1993, 11, 485.
34. Lanza A., Alba E., Re A., Tessarolo M., Leo L , Bellino R. et al.: "Endometrial carcinoma in breast cancer patients treated with tamoxifen". Eur. J. Gynecol. Oncol., 1994, 6, 455.
35. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O. et al.: "Effect of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial". Lancet, 1994, 343, 1318.
36. De Muylder X., Neven P, De Somer M., Van Belle Y., Vanderick G., De Muylder E.: "Endometrial lesions in patients undergoing tamoxifen therapy". Int. J. Gynaecol. Obstet., 1991, 36, 127.
37. Cohen I., Rosen D. J. D., Shapira J., Cordoba M., Giboa S., Altaras M. M. et al.: "Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic, postmenopausal women in a randomised breast cancer prevention trial". Lancet. 1994, 343, 1318.
38. Gal D., Kopel S., Bashevkin M., Lebowic J., Lev R., Tancer M. L.: "Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report". Gynecol. Oncol., 1991, 42, 120.
39. Wolf D., Jordan V. C.: "Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer". Gynecol. Oncol., 1992, 45, 118.
40. Rutqvist L. E., Johasson H., Signomklao T., Johansson U., Fornander T., Wilking N.: "Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies". J. Natl. Cancer Inst., 1995, 87, 645.
41. Mouridsen H. T., Rose C., Overgaard M. et al.: "Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 and DBCG 82 C". Acta Oncol., 1988, 27, 699.
42. Ryden S., Moller T., Hafstrom L. O. et al.: "Adjuvant therapy of breast cancer: compliance and data validity in a multicenter trial". Controlled Clin. Trials, 1986, 7, 290.
43. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L , Cronin W. M. et al.: "Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14". J. Nat. Cancer Instit., 1994, 86, 527.
44. Antunes C. M. F., Stolley P. D., Rosenhein N. B., Davies J. L., Tonascia J. A., Brown C. et al.: "Endometrial cancer and estrogen use report of a large case control study". N. Engl. J. Med., 1979, 300, 13.
45. Buring J. E., Bain C J., Ehrmann R. L.: "Conjugated estrogen use and risk of endometrial cancer" Am. J. Epidemiol., 1988, 24, 434.
46. Ewertz M., Schou G., Boice J. D.: "The joint effect of risk factors on endometrial cancer". Eur. J. Cancer Clin. Oncol., 1988, 24, 189.
47. Gray L. A., Christorpherson W. M., Hoover R. N.: "Estrogens and endometrial carcinoma". Obstet. Gynecol., 1977, 49, 385.
48. Hoogerland D. L., Buchler D. A., Crowley J. J., Carr W. F.: "Estrogen use: risk of endometrial carcinoma". Gynecol. Oncol., 1978, 6, 451.
49. Jelovsek F. R., Hammond C. B., Woodard B. H., Draffin R., Lee K. L., Creasman W. T. et al.: "Risk of exogenous estrogen therapy and endometrial cancer". Am. J. Obstet. Gynecol., 1980, 137, 85.
50. Jick H., Watkins R. N., Hunter J. R., Dinan B. J., Madsen S., Rothman K. J., Walker A. M.: "Replacement estrogens and endometrial cancer". N. Engl. J. Med., 1979, 300, 218.
51. Kelsey J. L., Li Volsi V. A., Holford T. R., Fischer D B., Mostow E. D., Schwartz P. E. et al.: "Case-control study of cancer of endometrium". Am. J. Epidemiol., 1982, 116, 333.
52. Koumantaki Y., Tzonou A., Koumantakis E., Kaklamani E , Aravantinos D., Trichopoulos D.: "A case-control study of cancer of teh endometrium in Athens". Int. J Cancer, 1989, 43, 795.
53. La Vecchia C., Franceschi S., Gallus G., Decarli A., Colombo E., Mangioni C. et al.: "Oestrogens and obesity as risk factors for endometrial cancer in Italy". Int. J. Epidemiol, 1982, 11, 120.
54. Mack T. M., Pike M. C., Henderson B. E., Pfeffer R. I., Gerkins V. R., Arthur M., Brown S. E.: "Estrogens and endometrial cancer in a retirement community". N. Engl. J. Med., 1976, 294, 1262.
55. McDonald T. W., Annegers J. F., O'Fallon W. M., Dockerty M. B., Malkasian G. D., Kurland L. T.: "Exogenous estrogen and endometrial cancer; case-control and incidence study". Am. J. Obstet. Gynecol., 1977, 127, 572.
56. Paganini-Hill A., Ross R. K., Henderson B. E.: "Endometrial cancer and patterns of use of oestrogen replacement therapy a cohort study". Br. J. Cancer, 1989, 59, 445.
57. Persson I., Adami H. O., Bergkvist L., Lindgren A., Petterson B., Hoover R., Schairer C.: "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study". Br. Med. J., 1989, 298, 147.
58. Shapiro S., Kaufman D. W., Slone D., Rosenberg L., Miettnen O. S., Stolley P. D. et al.: "Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium". N. Engl. J. Med., 1980, 303, 485.
59. Smith D. C., Prentice R., Thompson D. J., Herrmann W. L.: "Association exogenous estrogen and endometrial carcinoma". N. Engl. J Med., 1975, 293, 1164.
60. Weiss N. S., Szekely D. R., Austin D. F.: "Increasing incidence of endometrial cancer in the United States". N. Engl. J Med., 1976, 294, 1259.
61. Wigle D. T., Grace M., Smith S. O.: "Estrogen use and cancer of the uterine corpus in Alberta" Can. Med. Assoc., 1978, 118, 1276.
62. Ziel H. K., Finkle W. D : "Increased risk of endometrial carcinoma among users of conjugated estrogens". N. Engl. J. Med., 1975, 293, 1164
63. Fornader T., Cedermark, Mattsson A., Skoog L., Askergren J., Rutqvist L. E., Glas U., Silfversward C., Somell A., Wilking N., Hjalmar M. L.: "Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer". Lancet, 1989, 21, 111.
64. Van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A. L. A. M., Gimbrere C. H. F., Ottener R., Schouten L. J., Damhuis R. A. M., Bontenbal M., Diepenhorst F. W., van den Belt-Dusebout A. W., van Tinteren H.: "Risk of endometrial cancer after tamoxifen treatment of breast -cancer". Lancet, 1994, 343, 448.
65. Cook L. S., Weiss N. S., Schawartz S. M., White E., McKnight B., Moore D. E. et al.: "Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers". J. Nat. Cancer Inst., 1995, 20, 1359.
66. Sascò A. J., Chaplain G., Amoros E., Saez S.: "Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy". Epidemiology, 1996, 7, 9.
67. Grady D , Gebretsadik T., Kerlikowske K.: "Hormone replacement therapy and endometrial cancer risk: a metaanalysts". Obstet. Gynecol., 1995, 85, 304.
68. Stewart H. J : "The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish cancer trials breast group". Monogr. Natl. Cancer Inst, 1992, 11, 117.
69. Ribeiro E., Swindell R.: "The Christie Hospital adjuvant tamoxifen trial". Monogr. Natl. Cancer Inst., 1992, 11, 121.
70. Ingle N.: "Tamoxifen and endometrial cancer: new challenges for an 'old' drug". Gynecol. Oncol., 1994, 55, 161.
71. Magriples U., Naftolin F., Schwartz P. E., Caracanigiu M. L.: "High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Clin. Oncol., 1993, 11, 485.
72. Barakat R. R., Wong G., Curtin J. P., Vlamis V., Hoskins W. J.: "Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is associated with a higher incidence of adverse histologic features". Gynecol. Oncol., 1993, 55, 164.
73. Early breast cancer Trialists' Collaborative Group. "Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy: 133 randomised trials involving 31,000 reccurrences and 24,000 death among 75,000 women". Lancet, 1992, 339, 1, 71.
74. Cohen I., Rosen D. J. D., Tepper R. et al.: "Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in patients treated with tamoxifen". J. Ultrasound. Med., 1993, 5, 275.
75. Auteby E., Yagel S., Tacet D., Palti Z., Hocher-Celniker D.: "False sonographic appearance of endometrial neoplasia - postmenopausal women treated ultrasonographically". Lancet, 1992, 340, 433.